|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomassen I, van Gestel YR, van Ramshorst
B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH:
Peritoneal carcinomatosis of gastric origin: A population-based
study on incidence, survival and risk factors. Int J Cancer.
134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Angelica M, Gonen M, Brennan MF,
Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence
in completely resected gastric adenocarcinoma. Ann Surg.
240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smalley SR, Benedetti JK, Haller DG,
Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson
JA, Jessup JM, et al: Updated analysis of SWOG-directed intergroup
study 0116: A phase III trial of adjuvant radiochemotherapy versus
observation after curative gastric cancer resection. J Clin Oncol.
30:2327–2333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yurttas C, Hoffmann G, Tolios A, Haen SP,
Schwab M, Königsrainer I, Königsrainer A, Beckert S and Löffler MW:
Systematic review of variations in hyperthermic intraperitoneal
chemotherapy (HIPEC) for peritoneal metastasis from colorectal
cancer. J Clin Med. 7:5672018. View Article : Google Scholar
|
|
10
|
Tao Y, Guo Y, Liu W, Zhang J, Li X, Shen
L, Ru Y, Xue Y, Zheng J, Liu X, et al: AKT inhibitor suppresses
hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells.
Braz J Med Biol Res. 46:394–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Habash RW, Bansal R, Krewski D and Alhafid
HT: Thermal therapy, part 2: Hyperthermia techniques. Crit Rev
Biomed Eng. 34:491–542. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Habash RW, Bansal R, Krewski D and Alhafid
HT: Thermal therapy, part 1: An introduction to thermal therapy.
Crit Rev Biomed Eng. 34:459–489. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roti RJ: Cellular responses to
hyperthermia (40–46 degrees C): Cell killing and molecular events.
Int J Hyperthermia. 24:3–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koutcher JA, Barnett D, Kornblith AB,
Cowburn D, Brady TJ and Gerweck LE: Relationship of changes in pH
and energy status to hypoxic cell fraction and hyperthermia
sensitivity. Int J Radiat Oncol Biol Phys. 18:1429–1435. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tabuchi Y, Wada S, Furusawa Y, Ohtsuka K
and Kondo T: Gene networks related to the cell death elicited by
hyperthermia in human oral squamous cell carcinoma HSC-3 cells. Int
J Mol Med. 29:380–386. 2012.PubMed/NCBI
|
|
16
|
Tabuchi Y, Takasaki I, Wada S, Zhao QL,
Hori T, Nomura T, Ohtsuka K and Kondo T: Genes and genetic networks
responsive to mild hyperthermia in human lymphoma U937 cells. Int J
Hyperthermia. 24:613–622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malumbres M and Barbacid M: Mammalian
cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia Y, Zhao LM, Bai HY, Zhang C, Dai SL,
Lv HL and Shan BE: The tumor-suppressive function of miR-1296-5p by
targeting EGFR and CDK6 in gastric cancer. Biosci Rep.
39:BSR201815562019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amaya C, Kurisetty V, Stiles J, Nyakeriga
AM, Arumugam A, Lakshmanaswamy R, Botez CE, Mitchell DC and Bryan
BA: A genomics approach to identify susceptibilities of breast
cancer cells to ‘fever-range’ hyperthermia. BMC Cancer. 14:812014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen
Y, Tai F, Wang Y, Lin Y, Zhang Q, et al: Targeting the
BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast
cancer. Nat Commun. 9:52002018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Narikawa M, Umemura M, Tanaka R, Fujita T,
Yokoyama U, Ishigami T, Kimura K, Tamura K and Ishikawa Y: Acute
hyperthermia inhibits TGF-β1-induced cardiac fibroblast activation
via suppression of Akt signaling. Sci Rep. 8:62772018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kollmann K, Heller G, Schneckenleithner C,
Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M,
Schiefer AI, et al: A kinase-independent function of CDK6 links the
cell cycle to tumor angiogenesis. Cancer Cell. 24:167–181. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hydbring P, Malumbres M and Sicinski P:
Non-canonical functions of cell cycle cyclins and cyclin-dependent
kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tigan AS, Bellutti F, Kollmann K, Tebb G
and Sexl V: CDK6-a review of the past and a glimpse into the
future: From cell-cycle control to transcriptional regulation.
Oncogene. 35:3083–3091. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bellutti F, Tigan AS, Nebenfuehr S,
Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S,
Doma E, Prchal-Murphy M, et al: CDK6 antagonizes p53-induced
responses during tumorigenesis. Cancer Discov. 8:884–897. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dall'Acqua A, Sonego M, Pellizzari I,
Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G,
Califano D, et al: CDK6 protects epithelial ovarian cancer from
platinum-induced death via FOXO3 regulation. EMBO Mol Med.
9:1415–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scheicher R, Hoelbl-Kovacic A, Bellutti F,
Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C,
Salazar-Roa M, Zöchbauer-Müller S, Zuber J, et al: CDK6 as a key
regulator of hematopoietic and leukemic stem cell activation.
Blood. 125:90–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
